» Articles » PMID: 34245239

DISMIR: Deep Learning-based Noninvasive Cancer Detection by Integrating DNA Sequence and Methylation Information of Individual Cell-free DNA Reads

Overview
Journal Brief Bioinform
Specialty Biology
Date 2021 Jul 10
PMID 34245239
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Detecting cancer signals in cell-free DNA (cfDNA) high-throughput sequencing data is emerging as a novel noninvasive cancer detection method. Due to the high cost of sequencing, it is crucial to make robust and precise predictions with low-depth cfDNA sequencing data. Here we propose a novel approach named DISMIR, which can provide ultrasensitive and robust cancer detection by integrating DNA sequence and methylation information in plasma cfDNA whole-genome bisulfite sequencing (WGBS) data. DISMIR introduces a new feature termed as 'switching region' to define cancer-specific differentially methylated regions, which can enrich the cancer-related signal at read-resolution. DISMIR applies a deep learning model to predict the source of every single read based on its DNA sequence and methylation state and then predicts the risk that the plasma donor is suffering from cancer. DISMIR exhibited high accuracy and robustness on hepatocellular carcinoma detection by plasma cfDNA WGBS data even at ultralow sequencing depths. Further analysis showed that DISMIR tends to be insensitive to alterations of single CpG sites' methylation states, which suggests DISMIR could resist to technical noise of WGBS. All these results showed DISMIR with the potential to be a precise and robust method for low-cost early cancer detection.

Citing Articles

Overview and Prospects of DNA Sequence Visualization.

Wu Y, Xie X, Zhu J, Guan L, Li M Int J Mol Sci. 2025; 26(2).

PMID: 39859192 PMC: 11764684. DOI: 10.3390/ijms26020477.


Artificial intelligence and machine learning in cell-free-DNA-based diagnostics.

Tsui W, Ding S, Jiang P, Lo Y Genome Res. 2025; 35(1):1-19.

PMID: 39843210 PMC: 11789496. DOI: 10.1101/gr.278413.123.


MethylBERT enables read-level DNA methylation pattern identification and tumour deconvolution using a Transformer-based model.

Jeong Y, Gerhauser C, Sauter G, Schlomm T, Rohr K, Lutsik P Nat Commun. 2025; 16(1):788.

PMID: 39824848 PMC: 11742067. DOI: 10.1038/s41467-025-55920-z.


Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges.

Li L, Sun Y MedComm (2020). 2024; 5(11):e766.

PMID: 39525954 PMC: 11550092. DOI: 10.1002/mco2.766.


Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application.

Su L, Bu J, Yu J, Jin M, Meng G, Zhu X Clin Transl Med. 2024; 14(11):e70066.

PMID: 39462685 PMC: 11513202. DOI: 10.1002/ctm2.70066.


References
1.
Guo W, Fiziev P, Yan W, Cokus S, Sun X, Zhang M . BS-Seeker2: a versatile aligning pipeline for bisulfite sequencing data. BMC Genomics. 2013; 14:774. PMC: 3840619. DOI: 10.1186/1471-2164-14-774. View

2.
Zeng T, Wang D, Chen J, Tian Y, Cai X, Peng H . LncRNA-AF113014 promotes the expression of Egr2 by interaction with miR-20a to inhibit proliferation of hepatocellular carcinoma cells. PLoS One. 2017; 12(5):e0177843. PMC: 5438171. DOI: 10.1371/journal.pone.0177843. View

3.
Schwarzenbach H, Hoon D, Pantel K . Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11(6):426-37. DOI: 10.1038/nrc3066. View

4.
Bitzer M, Horger M, Giannini E, Ganten T, Worns M, Siveke J . Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study. J Hepatol. 2016; 65(2):280-8. DOI: 10.1016/j.jhep.2016.02.043. View

5.
Hebestreit K, Dugas M, Klein H . Detection of significantly differentially methylated regions in targeted bisulfite sequencing data. Bioinformatics. 2013; 29(13):1647-53. DOI: 10.1093/bioinformatics/btt263. View